Application of a kind of phycocyanin peptide in the preparation of anti-pulmonary fibrosis medicine

A technology for phycocyanin and pulmonary fibrosis, applied in the field of phycocyanin peptides

Active Publication Date: 2022-06-07
CHINA PHARM UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been reported that phycocyanin has anti-pulmonary fibrosis effect [6-7] , the phycocyanin peptide of the present invention is derived from the beta subunit of cyanobacterium phycocyanin, has 20 amino acid residues, and the amino acid sequence is PGSSVAVGVGKMKEAALAIV, and there is no report of its anti-pulmonary fibrosis activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a kind of phycocyanin peptide in the preparation of anti-pulmonary fibrosis medicine
  • Application of a kind of phycocyanin peptide in the preparation of anti-pulmonary fibrosis medicine
  • Application of a kind of phycocyanin peptide in the preparation of anti-pulmonary fibrosis medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0035] 1. Synthesis and Purity of Phycocyanin Peptides

[0036] The phycocyanin peptide was synthesized by Shanghai Bioengineering Co., Ltd. with a purity of 98.9% ( figure 1 A), mass spectrometry identified the molecular weight as 1884 Da ( figure 1 B).

[0037] 2. Anti-pulmonary fibrosis effect of phycocyanin peptides

[0038] Animal experiment

[0039] A mouse model of pulmonary fibrosis induced by oleic acid [8-10], 60 clean-grade ICR mice (provided by the Comparative Medical Center of Yangzhou University, animal production license number: SCXK (Su) 2008-0005), male, 4-6 weeks old, weighing 20-25g, were randomly selected for the experiment. Divided into 7 groups with 8-9 animals in each group, namely normal group, model group, phycocyanin peptide low dose group (1mg / Kg), phycocyanin peptide medium dose group (3mg / Kg), phycocyanin peptide High dose group (9mg / Kg), positive drug group, phycocyanin group (200mg / Kg). Except for the normal control group, the other groups ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the application of a phycocyanin peptide in the preparation of anti-pulmonary fibrosis medicine, the amino acid sequence of which is PGSSVAVGVGKMKEAALAIV. Phycocyanin peptide can significantly improve the degree of fibrosis in pulmonary fibrosis model mice, protect the alveolar structure, reduce the inflammatory response in the fibrosis process, and reduce the collagen deposition in lung tissue. The results of in vitro experiments demonstrated that phycocyanin peptides could significantly down-regulate the collagen expression and epithelial-mesenchymal transition of human lung adenocarcinoma basal epithelial cells A549 induced by TGFβ1; Transformation of fibroblasts. Both in vivo and in vitro experimental results prove that phycocyanin peptide has significant anti-pulmonary fibrosis efficacy, and has the prospect of being used as a drug for treating or improving pulmonary fibrosis.

Description

technical field [0001] The invention relates to a phycocyanin peptide, in particular to a phycocyanin peptide with an anti-pulmonary fibrosis effect and its application in the preparation of medicines and health products for preventing and treating pulmonary fibrosis. Background technique [0002] Pulmonary fibrosis (PF) is a disease of unknown etiology characterized by diffuse alveolitis and alveolar structural disorders that eventually lead to pulmonary fibrosis. The clinical manifestations are gradually increasing dyspnea, accompanied by irritating dry cough, occasional phlegm and blood, physical weakness, loss of appetite, weight loss, weight loss and other symptoms. The disease progressed further and eventually died of respiratory failure. At present, PF patients do not respond well to traditional treatment drugs, and their morbidity and mortality are increasing year by year, and their survival time is short and the prognosis is very poor, which is almost no different ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/16A61P11/00
CPCA61K38/164A61P11/00
Inventor 欧瑜李启豪张昭宇裴欣孙仲侃
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap